Bismuth subsalicylate/calcium carbonate

A cell-permeable and selective inhibitor of human Acetyl-CoA carboxylase 2 (ACC2) (IC 50 = 2.8 &#181M), which does not inhibit human ACC1 at all at concentrations up to 100 &#181M, in vitro .

Application Reagent for the preparation of activated 4-nitrophenyl esters of N -protected amino acids. Reagent for the synthesis of 4-nitrophenyl active esters of amino acids.

A cell-permeable furan carboxamide compound that acts as a potent, reversible, and ATP-competitive cFMS/CSF-1R inhibitor that blocks cFMS autophosphorylation both in CSF-1/M-CSF-stimulated HEK-293 cells (IC 50 = 76 nM) and in cell-free in vitro

Primary bile acid. Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, refrigerate (4&#176C).

Primary bile acid. Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, refrigerate (4&#176C).

A cell-permeable alkynedihydrocinnamic acid that acts as a potent GPR40/FFA1 agonist (EC 50 = 40.7 nM in inducing Ca 2+ mobilization in hFFA1-expressing 1321N1 cells) with &gt100-fold selectivity over GPR43/FFA2, GPR41/FFA3, and a panel of 56

A potent, reversible inhibitor of granzyme B and caspase-8 (K i = 1 nM). Also inhibits caspase-1 (&lt6 nM), caspase-6 (5.

A reversible inhibitor of Granzyme B that also inhibits caspase-8. Granzyme B is a protease involved in the induction of rapid target cell death by cytotoxic lymphocytes.

A cell-permeable thiosemicarbazone copper chelator that potently blocks the HDL receptor SR-BI- (scavenger receptor, class B, type I) mediated lipid uptake (IC 50 = 21 and 57 nM against DiI and CE uptake, respectively, from DiI-HDL and CE-HDL using

A purine derivative that acts as a potent, reversible and selective inhibitor of p34 cdk 1 /cyclin B (IC 50 = 7 &#181M) and related kinases including p33 cdk 2 /cyclin A (IC 50 = 7 &#181M), p33 cdk 2 /cyclin E (IC 50 = 7 &#181M), p33 cdk 5 /p35

A purine derivative that acts as a potent, reversible and selective inhibitor of p34 cdk 1 /cyclin B (IC 50 = 7 &#181M) and related kinases including p33 cdk 2 /cyclin A (IC 50 = 7 &#181M), p33 cdk 2 /cyclin E (IC 50 = 7 &#181M), p33 cdk 5 /p35

Native proteinase activated receptor-2- (PAR-2) specific agonist, SLIGRL-NH 2 , modified with an N-terminal furoyl group to increase its potency and resistance to metabolic degradation. Shown to activate [Ca 2+ ] i mobilization in PAR-2-expressing